Drugs in MeSH Category GABA Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Sub Teva Pharms	CLOZAPINE	clozapine	TABLET;ORAL	076809-003	Dec 16, 2005	AB	RX	No	No
Ivax Sub Teva Pharms	CLOZAPINE	clozapine	TABLET;ORAL	074949-003	Jul 31, 2003		RX	No	No
Accord Hlthcare	CLOZAPINE	clozapine	TABLET;ORAL	202873-002	Nov 25, 2015	AB	RX	No	No
Mylan	CLOZAPINE	clozapine	TABLET, ORALLY DISINTEGRATING;ORAL	201824-002	Sep 15, 2015	AB	RX	No	No
Zydus Pharms	CLOZAPINE	clozapine	TABLET;ORAL	209480-004	Dec 6, 2017		DISCN	No	No
Aurobindo Pharma	CLOZAPINE	clozapine	TABLET, ORALLY DISINTEGRATING;ORAL	212923-003	Dec 12, 2024	AB	RX	No	No

GABA Antagonists Market Analysis and Financial Projection

The market dynamics and patent landscape for GABA antagonists—drugs that inhibit GABA receptors to modulate neurological functions—are shaped by evolving therapeutic applications, competitive R&D, and expanding intellectual property strategies. Here's an analysis based on current trends and innovations:

---

Market Dynamics

Growth Drivers

1. Neurological and Psychiatric Disorders:
   The rising prevalence of Alzheimer’s, Parkinson’s, and anxiety disorders has spurred demand for GABA antagonists, which show promise in cognitive enhancement and mood regulation[1][7]. For example, α5-GABA_A receptor antagonists like L-655,708 are being tested for memory improvement without convulsant side effects[8].

2. Niche Therapeutic Applications:
   GABA antagonists are explored for excessive sleepiness (e.g., shift work disorder) and sedation/anesthesia. Sage Therapeutics recently patented neuroactive steroids targeting GABA receptors for sedation, highlighting clinical versatility[2][4].

3. Aging Populations:
   With over 20% of the global population projected to be over 60 by 2050, age-related neurodegenerative diseases are driving market expansion[1][12].

4. Regional Growth:
   North America dominates due to FDA approvals and high CNS disorder prevalence, while Asia-Pacific emerges as a high-growth region with increasing healthcare investments[1][12].

Market Challenges

• Regulatory Hurdles: Development costs and stringent approval processes delay commercialization. For instance, Zealand Pharma faced FDA rejection for glepaglutide despite positive trial data[13].
• Competition from Agonists: GABA agonists like baclofen and propofol currently dominate the $6B+ market, overshadowing antagonists[12].

---

Patent Landscape

Key Innovations and Players

Company/Patent	Focus	Status/Indication
Sage Therapeutics (US20240025942)	GABA modulators for sedation/anesthesia	Preclinical/Phase I trials[4]
Sanofi (RU-5135)	GABAA antagonist	Discontinued (formerly for anxiety)[9]
Ciba-Geigy (CGP-54626)	GABAB receptor antagonist	Preclinical research[14]
EcoSmart Technologies	Pesticidal GABA antagonists (thymol derivatives)	Granted (cross-industry use)[16]

Trends

• Cognitive Enhancement: Negative allosteric modulators (NAMs) targeting α5-GABA_A receptors (e.g., α5IA) aim to improve memory in Alzheimer’s patients[8].
• Combination Therapies: Patents increasingly cover GABA antagonists paired with other agents (e.g., SSRIs) to enhance efficacy in depression and epilepsy[4][14].
• Cross-Industry Applications: GABA antagonists like fipronil are repurposed in agriculture as pesticides, broadening IP portfolios[16].

---

Pipeline and Future Outlook

• Clinical Pipeline: Over 15 GABA antagonist candidates are in development, primarily targeting CNS disorders. Examples include AgeneBio’s α5-GABA_A NAMs and Cerevel Therapeutics’ GABA_B antagonists[11].
• Emerging Markets: Asia-Pacific’s CAGR of 8.2% reflects growing R&D investments and partnerships with global pharma[1][12].
• Patent Analysis Growth: The patent landscape sector is projected to reach $4.1B by 2033, driven by AI-driven analytics and crowded fields like neurology[17].

---

Strategic Opportunities

• White Space in Indications: Underexplored areas include autism and treatment-resistant depression, where GABA dysfunction plays a key role[8][11].
• Biosimilars and Generics: With key patents expiring (e.g., Stelara), biosimilars like Biocon’s Yesintek could disrupt markets[13].

---

Key Takeaways

• GABA antagonists are gaining traction in cognitive and sleep disorders, though lag behind agonists in market share.
• Patent filings reflect innovation in targeted therapies and cross-industry applications.
• Regulatory and competitive pressures necessitate strategic IP management and partnerships.

Highlight: "Increased funding by government and private organizations across emerging economies for treatment of neurological disorders will provide beneficial opportunities for the GABA market." – GlobalData[4][11].

References

1. https://www.databridgemarketresearch.com/reports/global-gaba-receptor-agonist-market
2. https://patents.google.com/patent/US20110028418A1/en
3. https://pubmed.ncbi.nlm.nih.gov/18590768/
4. https://www.pharmaceutical-technology.com/data-insights/sage-therapeutics-files-patent-for-gaba-modulator-pharmaceutical-compositions-for-sedation-and-anesthesia/
5. https://patents.google.com/patent/US20100144888A1/en
6. https://www.wjgnet.com/2218-6220/full/v4/i2/24.htm
7. https://www.verifiedmarketresearch.com/product/gaba-market/
8. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2019.00179/full
9. https://synapse.patsnap.com/drug/32714f31787547bfb2b9063812b9c99f
10. https://meshb.nlm.nih.gov/record/ui?ui=D058787
11. https://www.globaldata.com/store/report/gamma-aminobutyric-acid-receptor-subunit-alpha-5-drugs-in-development-analysis/
12. https://www.globenewswire.com/news-release/2018/03/26/1452776/0/en/Global-GABA-Receptor-Agonist-Drug-Market-Dosage-Price-Clinical-Pipeline-Outlook-2024-49-Drugs-in-Clinical-Pipeline-28-Marketed-Drugs.html
13. https://www.biospace.com/biospace-fda-decision-tracker
14. https://synapse.patsnap.com/drug/8e46d5443b9443b6af865d54c6a123c4
15. https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D27)
16. https://patents.justia.com/patent/20100144888
17. https://caldwelllaw.com/news/how-patent-landscape-analysis-drives-business-growth/